Shanghai Microport Medbot (group) Co., Ltd. Class H · HKEX:2252
Shanghai Microport Medbot (group) Co., Ltd. Class H — FY2024 Earnings Presentation
27 slides from Shanghai Microport Medbot (group) Co., Ltd. Class H's earnings presentation, April 2025
Slide 1: 2024 Annual Results Presentation
2024 Annual Results Presentation April 2025
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of Shanghai MicroPort MedBot (Group) Co., Ltd., and no part of it shall form the
Slide 3: Agenda
AGENDA FY24 Business Highlights Product Pipeline Update Financial Review Appendix 3
Slide 4: 2024 Business Highlights
2024 Business Highlights 257mn 100+ Revenue (RMB) 146% YoY Cumulative orders Free cash outflow 388mn Adj net loss 483mn 60+ 40+ 7 Improved 42% YoY Narrowed 45% YoY Toumai SkyWalker R-ONE 20+ 300+ Orders received in Remote surgeries completed by Toumai® Toumai ®’s 1st year of overseas penetration 10+
Slide 5: Strong Revenue Growth with Robust Domestic Market and Surged Overseas Penetration
Business Highlights Strong Revenue Growth with Robust Domestic Market and Surged Overseas Penetration (RMB mn) Australia South 1% America Asia Toumai® 3% (other than the PRC) 11% Revenue ➔ 39 units of new orders, among which over 20 units from overseas market, covering 4 major continents - Europe, A
Slide 6: Remarkable Global Market Exploration Striding Forward across Five Continents
Business Highlights Remarkable Global Market Exploration Striding Forward across Five Continents Regulatory approvals from mainstream markets Toumai® - obtained approvals from ~20 countries/regions, incl. CE mark etc Canada UK SkyWalkerTM – obtained approvals from 8 Netherland Belarus countries/regi
Slide 7: Demonstration of Leading Edge and Clinical Competency through Large-scale surgeries
Business Highlights Demonstration of Leading Edge and Clinical Competency through Large-scale surgeries China Case studies Gansu Provincial Hospital Surgical procedures Toumai® assisted in 300+ surgeries Toumai® Maintained No.1 in terms of clinical operations among domestic brands Shanghai Pulmonary
Slide 8: Global Market Access Accelerated with Well-recognized Clinical Performance
Business Highlights Global Market Access Accelerated with Well-recognized Clinical Performance SkyWalkerTM Toumai® Single-port Obtained 4 more approvals from India, Approved by NMPA in Feb 2025 Japan, UK and Canada in 2024 (Cumulatively 8 international approvals incl. FDA and CE mark) Toumai® DFVisi
Slide 9: Continue to Spearhead the Application of Remote Surgical Technology
Business Highlights Continue to Spearhead the Application of Remote Surgical Technology Lhasa – Beijing Orlando, USA – São Paulo, Brazil World’s 1st satellite-enabled China – Benin 1st remote human surgery robot-assisted surgery world’s 1st remote surgery by in South America Angola, Africa shipborne
Slide 10: Improved Operational Effectiveness on Stringent Cost-optimization Strategies
Business Highlights Improved Operational Effectiveness on Stringent Cost-optimization Strategies Optimizing Adjusted Net Loss Free Cash Outflow Gross profit Operational Narrowed Decreased Efficiency (RMB million) (RMB million) (RMB million) (RMB million) 11.5% R&D S&M Admin 1,110.3 15.9% 86.2 982.4
Slide 11: Agenda
AGENDA FY24 Business Highlights Product Pipeline Update Financial Review Appendix 11
Slide 12: Comprehensive product offering covering all major and fast-growing surgical specialties
Product Pipeline Update Comprehensive product offering covering all 5 major and fast-growing surgical specialties Medical Device Surgical Product Clinical Trial/ Specialty Product Indicated Application Classification Design Development Design Validation Clinical Evaluation Registration Application T
Slide 13: Flagship product – Toumai Laparoscopic Surgical Robot
Product Pipeline Update Flagship product– Toumai® Laparoscopic Surgical Robot Multiple generations of Domestic commercialization on track Toumai® clinical progress • Maintained leading position, #1 market share among domestic brands with ramped up wining bids and commercial installation: Completed t
Slide 14: Flagship product – SkyWalker Orthopedic Surgical Robot
Product Pipeline Update Flagship product – SkyWalkerTM Orthopedic Surgical Robot The 1st domestic surgical robot to expand into global market 2022 2023 2024 2025 China (NMPA) India China (NMPA, THA) US (FDA) Japan Brazil More to expect… Europe (CE) UK Australia Canada Continued decent global commerc
Slide 15: Flagship product – DFVision 3D Electronic Laparoscope
Product Pipeline Update Flagship product – DFVision® 3D Electronic Laparoscope Underlying technology to Steady commercialization – Obtained NMPA approval for contimuously optimize the high-end pioneer among domestic brands fluorescence imaging function vision platform for surgical robots Stereo visu
Slide 16: Natural Orifice Surgical Robot
Product Pipeline Update Natural Orifice Surgical Robot Trans-bronchial Surgical Robot Robot-assisted natural orifice surgery Product Surgery application ◼ Natural orifice surgical robots refer to robots that deliver surgical instruments to the target anatomy through natural pathways of the human bod
Slide 17: R-ONE Vascular Interventional Robot System
Product Pipeline Update R-ONE® Vascular Interventional Robot System Designed to operate with precision and NMPA approval perform specific movements CE mark Facilitate and enhance the interventional procedures performed on the patient Registration Approval Strong Commercialization Unique Synergy & Le
Slide 18: Mona Lisa Robotic Transperineal Prostate Biopsy System
Product Pipeline Update Mona Lisa Robotic Transperineal Prostate Biopsy System NMPA Approval Real-time ultrasound images displayed on the monitor FDA Approval during the biopsy procedure CE Marking TGA Approval The surgeon manually inserts the needle into the prostate to collect the biopsy cores HAS
Slide 19: Strong industrial operation capabilities for surgical robots
Product Pipeline Update Strong industrial operation capabilities for surgical robots g pply chain eadin R&D 1,333 u L S Multilayered supply chain system applications In-house designed components (509 granted) Scalable production of Toumai®, 509 SkyWalkerTM and consumables granted (338 in China; Annu
Slide 20: Agenda
AGENDA FY24 Business Highlights Product Pipeline Update Financial Review Appendix 20
Slide 21: Consolidated Financial Performance
Financial Review Consolidated Financial Performance REVENUE TOTAL NET LOSS FREE CASH FLOW Total revenue reached 257.2m with 146% growth, attributable to Total net loss decreased from 1,023.5m for the year 2023 to The success of revenue growth, costs reduction and the strong growth of sales in both d
Slide 22: Operating Expenses
Financial Review Operating Expenses R&D COST S&M EXPENSES ADMINISTRATIVE EXPENSES (RMB million) (RMB million) (RMB million) -59% -68% 25% 46% 13% 30% 755.8 26% 569.2 56% 238.4 207.9 308.7 184.0 170.5 126.4 55.3 2022 2023 2024 2022 2023 2024 2022 2023 2024 R&D 308.7m, 46% decline YoY S&M 207.9m, 13%
Slide 23: In Closing
In Closing We delivered record revenue and robust momentum to drive continuous growth We enjoy large, cross-border market opportunities Our comprehensive product pipeline enables technology integration, stimulates sales synergy, and provides integrated diagnostic and treatment solutions We are posit
Slide 24: Agenda
AGENDA FY24 Business Highlights Product Pipeline Update Financial Review Appendix 24
Slide 25: Appendix I - Consolidated Balance Sheet
Appendix I - Consolidated Balance Sheet Unit: RMB'000 31 Dec 2024 31 Dec 2023 Var. Unit: RMB'000 31 Dec 2024 31 Dec 2023 Var. Non-current assets CAPITAL AND RESERVES Share capital 1,006,194 958,594 5% Property, plant and equipment 297,371 367,017 -19% Intangible assets 3,972 9,537 -58% Reserves (727
Slide 26: Appendix II - Consolidated P&L
Appendix II - Consolidated P&L Unit: RMB'000 2024 2023 Var. Revenue 257,249 104,592 146% Cost of sales (171,029) (89,898) 90% Gross profit 86,220 14,694 487% Other net income (3,168) (13,342) -76% Selling and marketing expenses (207,934) (238,428) -13% Administrative expenses (55,282) (126,361) -56%
Slide 27: Thank You
a 4 > >)MEDBOT ~~~ o} PXGUANES A 3 THANK YOU. oO Les A (RSS) GIS)
Shanghai MicroPort MedBot (Group) — FY2024 Earnings Presentation on 6ix